Singapore, Jan. 8 -- Iktos, a leader in Artificial Intelligence (AI) and Robotics applied to drug discovery, announced a landmark multi-target collaboration agreement with Servier, an international independent pharmaceutical company governed by a foundation, leveraging Iktos' AI-orchestrated discovery platform to accelerate the design and optimization of novel small-molecule therapeutics across several therapeutic areas, including oncology and neurology.

The multi-year agreement, with a total potential deal value that could exceed €1 billion, including upfront, research funding, and milestone payments, will combine Iktos' advanced AI-enabled molecular design technologies with Servier's scientific, translational, and clinical develo...